乙肝肝硬化、慢性乙肝患者相关生化指标差异对比研究
Comparative Study on the Difference of Biochemical Indexes in Patients with Hepatitis B Cirrhosis and Chronic Hepatitis B
DOI: 10.12677/ACM.2023.13112477, PDF,   
作者: 钟 君*：青岛大学，山东 青岛；牛庆慧#：青岛大学附属医院肝脏病中心，山东 青岛
关键词: 乙肝肝硬化；慢性乙肝；生化指标；血常规；Hepatitis B Cirrhosis； Chronic Hepatitis B； Biochemical Index； Blood Routine Examination
摘要: 目的：对比分析乙肝肝硬化、慢性乙肝患者相关生化指标差异。方法：回顾分析我院2021年1月~2022年12月我院收治43例乙肝肝硬化(乙肝肝硬化组)和慢性乙肝(慢性乙肝组)患者的临床检查资料，对比两组血常规、生化指标、凝血指标和肿瘤标志物检测结果。结果：乙肝肝硬化组的白细胞计数明显高于慢性乙肝组(P > 0.05)，丙转氨酶、谷草转氨酶、直接胆红素、总胆红素、胱抑素C及总胆汁酸、活化部分凝血活酶时间、凝血酶时间、凝血酶原时间和D-二聚体、甲胎蛋白、癌胚抗原和糖链抗原125均明显高于慢性乙肝组，血红蛋白和血小板计数、白蛋白和肾小球滤过率及纤维蛋白原明显低于慢性乙肝组(P < 0.05)。结论：通过检测明确血常规、生化指标、凝血指标、肿瘤标志物差异，能够诊断乙肝肝硬化、慢性乙肝，利于临床尽早开展乙肝肝硬化防治措施，延缓病情进展，降低癌变风险。
Abstract: Objective: To compare and analyze the differences of biochemical indexes in patients with hepatitis B cirrhosis and chronic hepatitis B. Methods: The clinical examination data of 43 patients with hep-atitis B cirrhosis (hepatitis B cirrhosis group) and chronic hepatitis B (chronic hepatitis B group) admitted to our hospital from January 2021 to December 2022 were retrospectively analyzed, and the blood routine, biochemical indexes, coagulation indexes and tumor markers were compared between the two groups. Result: The WBC count in hepatitis B cirrhosis group was significantly higher than that in chronic hepatitis B group (P > 0.05), and the pyruvic transaminase, glutamic ox-alacetic transaminase, direct bilirubin, total bilirubin, cystatin C and total bile acid, activated partial thromboplastin time, thrombin time, prothrombin time, D-dimer, alpha-fetoprotein, carcinoem-bryonic antigen and glycochain antigen 125 were significantly higher than those in chronic hepati-tis B group. Hemoglobin and platelet count, albumin and glomerular filtration rate and fibrinogen were significantly lower than those in chronic hepatitis B group (P < 0.05). Conclusion: The differ-ences in blood routine, biochemical indexes, coagulation indexes and tumor markers can diagnose hepatitis B cirrhosis and chronic hepatitis B, which is conducive to clinical prevention and treat-ment of hepatitis B cirrhosis as early as possible, delay the progression of the disease and reduce the risk of cancer.
文章引用：钟君, 牛庆慧. 乙肝肝硬化、慢性乙肝患者相关生化指标差异对比研究[J]. 临床医学进展, 2023, 13(11): 17665-17670. https://doi.org/10.12677/ACM.2023.13112477

参考文献

[1] 单姗, 赵连晖, 马红, 等. 肝硬化的定义、病因及流行病学[J]. 临床肝胆病杂志, 2021, 37(1): 14-16.
[2] Xiao, S.Y., Xie, W.H., Zhang, Y.H., et al. (2023) Changing Epidemiology of Cirrhosis from 2010 to 2019: Results from the Global Burden Disease Study 2019. Annals of Medicine, 55, Article 2252326. [Google Scholar] [CrossRef] [PubMed]
[3] Xu, J., Liu, K., Ma, Z., Lin, Y. and Pang, L. (2022) Explora-tion of Inflammation, Oxidative Stress, Adiponectin and Intestinal Flora in Patients with Hepatitis B, Liver Cirrhosis and Hepatocellular Carcinoma. Minerva Gastroenterol (Torino), 68, 365-367. [Google Scholar] [CrossRef] 
[4] 许雅洁, 尤文铮, 任万雷, 等. 肝活检病理学指标在肝硬化门静脉高压症诊断中的应用[J]. 临床肝胆病杂志, 2021, 37(12): 2935-2938.
[5] 杨思蕴, 吴敏华. 血生化检验联合肝功能检测在慢性乙型病毒性肝炎肝硬化诊断中的应用价值分析[J]. 山西医药杂志, 2023, 52(5): 382-385.
[6] 冼观秀, 张家明, 陈聪, 等. 乙型肝炎肝硬化患者自身抗体检测及与生化指标和肝纤维化指数的关系[J]. 中国医药科学, 2020, 10(21): 173-175+183.
[7] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846 -865.
[8] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 中华传染病杂志, 2019, 37(12): 711-736.
[9] 杨学平, 王雪梅, 王玥, 等. 血小板计数与脾面积比值和血小板计数与脾长径比值诊断乙肝肝硬化患者食管静脉曲张的对比研究[J]. 临床超声医学杂志, 2021, 23(3): 229-231.
[10] 刘华柱, 张献文, 张欢, 等. D-二聚体/血小板、纤维蛋白原/白蛋白预测乙肝肝硬化患者食管胃底静脉曲张破裂出血的临床价值[J]. 转化医学杂志, 2022, 11(3): 137-141.
[11] 陈显荣, 肖兵容, 成浩. B超与血清D-二聚体、白蛋白和总胆红素水平评价肝硬化和向原发性肝癌转化时的临床价值[J]. 中国卫生检验杂志, 2020, 30(20): 2489-2491.
[12] 陈博. 血清白蛋白、总胆固醇水平与肝炎肝硬化患者肝功能分级的相关性[J]. 中国民康医学, 2023, 35(8): 103-105.
[13] 张新丽, 卢东方, 朱昕赟. 白蛋白-胆红素评分对乙肝肝硬化失代偿期患者短期预后的评估价值[J]. 河南医学研究, 2022, 31(19): 3486-3489.
[14] 梁健夫, 张昌森, 谢晓婷. 生化检验中CHE、ALT及AST在肝硬化疾病诊断中的应用价值[J]. 中国医药科学, 2020, 10(11): 126-128.
[15] 周海丰. 慢性乙型肝炎、乙肝肝硬化及原发性肝癌患者血清CEA、AFP、CA125和CA199水平检测分析[J]. 临床合理用药杂志, 2020, 13(23): 124-126.

为你推荐